PMA device
t:slim X2 Insulin Pump with Basal-IQ Technology
Tandem Diabetes Care, Inc. · Automated Insulin Dosing , Threshold Suspend (OZO, Class III) · First FDA decision Jun 21, 2018, newest Jun 21, 2018Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
5
Naming "t slim X2"
MAUDE reports
171
Brand "t slim X2", since 2015
PubMed studies
14
Mentioning "t slim X2"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing t:slim X2 Insulin Pump with Basal-IQ Technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P180008 · Decided Jun 21, 2018 · 115 days after receipt
Device type: Automated insulin dosing , threshold suspend (OZO) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "t slim X2", any status and sponsor, newest update first.
Castilla-La Mancha Health ServiceAcademic, hospital or other
NCT06834334 · 189 participants · Start Feb 27, 2025 · Primary completion Oct 1, 2025
Device: MM780G; TTSX2 and 1 more · For: Type 1 Diabetes (T1D)
Sites: Badajoz, Spain; Terrassa, Spain; Ciudad Real, Spain
- Closed Loop Pumps vs. Traditional Open Loop Pumps in Managing Blood Glucose Levels in T1DM Patients Fasting in Ramadan.Status unknown
King Fahad Medical CityGovernment (non-federal)
NCT06416202 · 75 participants (planned) · Start Feb 1, 2024 · Primary completion Mar 11, 2024
Device: Advanced hybrid closed loop insulin pump · For: Insulin Pump Therapy
Sites: Riyadh, Saudi Arabia
Tandem Diabetes Care, Inc.Public (TNDM)
NCT05111301 · 30 participants · Start Nov 30, 2021 · Primary completion Aug 10, 2022
Device: Control-IQ technology 1.5 · For: Type 2 Diabetes Treated With Insulin
Sites: Rochester, Minnesota; New York, New York; Austin, Texas
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "t slim X2", and for the whole product code for context.
This brand
171 reports: 137 malfunction, 32 injury, 2 death
Whole product code OZO
424,597 reports: 337,031 malfunction, 86,136 injury, 1,411 death
Newest reports for this brand
MW6002288 · Received Sep 14, 2026 · Event dated May 5, 2026
Device type: Pump, Infusion, Insulin (LZG)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cancer
- TANDEM T-SLIM X2Injury
MW5187628 · Received May 4, 2026 · Event dated Apr 28, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
MW5178394 · Received Oct 31, 2025 · Event dated Oct 26, 2025
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Excess Flow or Over-Infusion
Patient problem as coded: Hypoglycemia
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "t slim X2"[tiab]. The summary above synthesizes these.
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy.
Sawyer A, Forlenza GP, Wadwa RP · Expert Rev Med Devices · 2025Review
- Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review.
Mameli C, Smylie GM, Marigliano M, et al. · Diabetes Ther · 2024Review
- Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology.
Shah VN, Akturk HK, Trahan A, et al. · J Diabetes Sci Technol · 2024
- Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.
Carlson AL, Graham TE, Akturk HK, et al. · J Diabetes Sci Technol · 2024Multicenter Study, Clinical Trial
- Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes.
Piona C, Passanisi S, Bombaci B, et al. · Diabetes Obes Metab · 2024Letter
- First Use of Control-IQ+ Technology in Newly Indicated Populations.
Assadi KZ, D'Souza EW, Pinsker JE, et al. · Diabetes Technol Ther · 2026
- Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.
De Meulemeester J, Fiorentino F, Picado N, et al. · Diabetes Technol Ther · 2026Multicenter Study
- Real-World Glycemic and Person-Reported Outcomes After Tandem Control-IQ Initiation in Children With Type 1 Diabetes.
De Meulemeester J, Valgaerts L, Massa G, et al. · J Clin Endocrinol Metab · 2025Observational Study, Multicenter Study
- Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes.
Levy CJ, Kanapka L, Brown SA, et al. · Diabetes Technol Ther · 2026Randomized Controlled Trial
- Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different Continuous Glucose Monitoring Sensors.
Akturk HK, Johnson AK, Welsh JB, et al. · J Diabetes Sci Technol · 2026Comparative Study
- One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.
De Meulemeester J, Keymeulen B, De Block C, et al. · Diabetologia · 2025Observational Study, Multicenter Study
- Off-label Use of the Tandem t: slim X2ࡊ with Control IQ® in Pregnancy: Insights from Five Case Studies.
Leite AR, Lopes R, Ferreira P, et al. · Curr Diabetes Rev · 2026Case Reports
Other devices of this type
Also filed under product code OZO.
- Minimed 530G SystemMedtronic, Inc. · PMA 2017
- MiniMed 630G Insulin Pump, Guardian Link (3) TransmitterMedtronic Minimed · PMA 2018
- Enlite SensorMedtronic, Inc. · PMA 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.